Somewhat Positive Media Coverage Somewhat Unlikely to Impact TherapeuticsMD (TXMD) Share Price
Media stories about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.625070955777 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- RSI Alert: TherapeuticsMD (TXMD) Now Oversold (nasdaq.com)
- Hot Stock That Must Be in Your Portfolio – TherapeuticsMD Inc (NASDAQ: TXMD) – Alpha Beta Stock (alphabetastock.com)
- RSI Alert: TherapeuticsMD (TXMD) Now Oversold – Nasdaq (nasdaq.com)
- TherapeuticsMD (TXMD) Cut to “Strong Sell” at BidaskClub (americanbankingnews.com)
- TherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer (americanbankingnews.com)
Shares of TherapeuticsMD (TXMD) opened at $5.51 on Monday. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30. The stock has a market cap of $1,190.00, a PE ratio of -14.13 and a beta of 0.99.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the transaction, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 23.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact TherapeuticsMD (TXMD) Share Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/02/05/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-therapeuticsmd-txmd-share-price.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.